
    
      To examine the feasibility of using biodynamic imaging (BDI) as a chemosensitivity assay on
      fresh tumor samples obtained by core needle biopsy from patients planned to receive routine
      care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the
      pancreas.
    
  